SynthesisDiabetes, obesity & metabolism2025

Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.

Masashi Hasebe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.